Antibiotic Treatment of Vertebral Osteomyelitis caused by Methicillin-Susceptible Staphylococcus aureus: A Focus on the Use of Oral β-lactams

Background: Vertebral osteomyelitis (VO) is a rare but serious condition, and a potentially significant cause of morbidity.Methicillin-susceptible Staphylococcus aureus (MSSA) is the most common microorganism in native VO.Long-term administration of parenteral and oral antibiotics with good bioavailability and bone penetration is required for therapy.Use of oral β-lactams against staphylococcal bone and joint infections in adults is not generally recommended, but some experts recommend oral switching with β-lactams.This study aimed to describe the current status of antibiotic therapy and treatment outcomes of oral switching with β-lactams in patients with MSSA VO, and to assess risk factors for treatment failure.Materials and Methods: This retrospective study included adult patients with MSSA VO treated at nine university hospitals in Korea between 2005 and 2014.Treatment failure was defined as infection-related death, microbiological relapse, neurologic deficits, or unplanned surgical procedures.Clinical characteristics and antibiotic therapy in the treatment success and treatment failure groups were compared.Risk factors for treatment failure were identified using the Cox proportional hazards model.Results: A total of 100 patients with MSSA VO were included.All patients were treated, initially or during antibiotic therapy, with one or more parenteral antibiotics.Sixty-nine patients received one or more oral antibiotics.Antibiotic regimens were diverse and durations of parenteral and oral therapy differed, depending on the patient and the hospital.Forty-two patients were treated with parenteral and/or oral β-lactams for a total duration of more than 2 weeks.Compared with patients receiving parenteral β-lactams only, no significant difference in success rates was observed in patients who received oral β-lactams for a relatively long period.Sixteen patients had treatment failure.Old age (adjusted hazard ratio [HR] 5.600, 95% confidence interval [CI] 1.402 -22.372,P = 0.015) and failure to improve C-reactive protein